ArticleInternational journal of clinical oncology2026
A prospective study evaluating the impact of waiting time on blood testing and clinical workflows in cancer patients.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundLong waiting times on chemotherapy days increase patient burden. Pre-visit blood sampling may streamline workflows; however, its real-world impact remains unclear.
methodsThis prospective study collected data on waiting times for pre-visit vs same-day blood sampling in 50 cancer patients receiving chemotherapy between October 2024 and February 2025 at St. Marianna University Hospital. Pre‑visit and same‑day blood sampling was compared in the same patients across four waiting times: (i) check-in to consultation, (ii) check-in to check-out, and (iii-iv) extended measures incorporating travel time. For times (iii) and (iv), travel time during pre-visit was also included. Patient and physician satisfaction and indirect costs were also evaluated.
resultsThe median waiting time from check-in to consultation was 1.8 and 2.2 h for pre-visit and same-day sampling, respectively; when chemotherapy and check-out were included (ii), total duration was similar (6.3 vs 6.3 h). Extended measures (iii-iv) tended to be longer with pre-visit sampling. After excluding the two outliers, waiting time from check-in to chemotherapy was significantly shorter for pre-visit vs same-day sampling (3.3 vs 3.9 h, p=0.025). Patient satisfaction was favorable, and 24.0% of patients reported reduced burden. Indirect costs improved by approximately 1198 Japanese yen per patient, with benefits reported in approximately half of the cases. Subgroup analyses suggested greater benefits for patients living within 30 min of both pre-visit blood sampling and chemotherapy facilities.
conclusionsPre-visit blood sampling may reduce waiting time and perceived burden for selected patients, although overall time savings were modest. Trial registration University Hospital Medical Information Network (UMIN) Clinical Trials Registry: UMIN000055757.
Indexed as
Identifiers
42892660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.